Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart + Anlotinib + Chemotherapy + Radiotherapy for First-line ES-SCLC
NCT07538271Phase 2Not yet recruiting
- Start
- Apr 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of benmelstobart and anlotinib in small cell lung cancer (SCLC). Primary endpoint: Objective Response Rate up to 24 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
benmelstobartanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07538271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07538271.